AU2014369457B2 - Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors - Google Patents
Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors Download PDFInfo
- Publication number
- AU2014369457B2 AU2014369457B2 AU2014369457A AU2014369457A AU2014369457B2 AU 2014369457 B2 AU2014369457 B2 AU 2014369457B2 AU 2014369457 A AU2014369457 A AU 2014369457A AU 2014369457 A AU2014369457 A AU 2014369457A AU 2014369457 B2 AU2014369457 B2 AU 2014369457B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- amino
- pyrimidin
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(CC*(C1)c2ccc(*(C)(C)C3(C)*=C(*(C)C*(c(c(N)ccc4)c4N)C4=O)C4=C*3)cc2)C1=N Chemical compound C*(CC*(C1)c2ccc(*(C)(C)C3(C)*=C(*(C)C*(c(c(N)ccc4)c4N)C4=O)C4=C*3)cc2)C1=N 0.000 description 2
- RXFFNESXLYNPLX-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc3cc(CO)c(C4CCNCC4)cc3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc3cc(CO)c(C4CCNCC4)cc3)ncc2C1=O RXFFNESXLYNPLX-UHFFFAOYSA-N 0.000 description 2
- MHMOUKLUMPQOEV-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc3ccc(CN4CCNCC4)cc3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc3ccc(CN4CCNCC4)cc3)ncc2C1=O MHMOUKLUMPQOEV-UHFFFAOYSA-N 0.000 description 2
- KMQLDJJMLMAAJT-UHFFFAOYSA-N CC(C)(C1)NCCN1c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound CC(C)(C1)NCCN1c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O KMQLDJJMLMAAJT-UHFFFAOYSA-N 0.000 description 1
- SZCJLDNKZMAJKR-UHFFFAOYSA-N CC(C)(C1)NCCN1c(cc1)ccc1Nc(nc1N(C)CN2c(cccc3)c3Cl)ncc1C2=O Chemical compound CC(C)(C1)NCCN1c(cc1)ccc1Nc(nc1N(C)CN2c(cccc3)c3Cl)ncc1C2=O SZCJLDNKZMAJKR-UHFFFAOYSA-N 0.000 description 1
- NUUYZLRTSOAJJV-UHFFFAOYSA-N CC(C)N(CC1)CCN1c(cc1)c(CO)cc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound CC(C)N(CC1)CCN1c(cc1)c(CO)cc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O NUUYZLRTSOAJJV-UHFFFAOYSA-N 0.000 description 1
- CPIUBIQPIQXPIC-UHFFFAOYSA-N CCC(N(CC1)CCN1c(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)=O Chemical compound CCC(N(CC1)CCN1c(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)=O CPIUBIQPIQXPIC-UHFFFAOYSA-N 0.000 description 1
- KGMYLTSFAPTXIB-UHFFFAOYSA-N CCNCc(cc(cc1)Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)c1N1CCOCC1 Chemical compound CCNCc(cc(cc1)Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)c1N1CCOCC1 KGMYLTSFAPTXIB-UHFFFAOYSA-N 0.000 description 1
- AIHHGFLJFSDSFZ-UHFFFAOYSA-N CN(C(CC1)C2)C1CN2c(c(CO)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound CN(C(CC1)C2)C1CN2c(c(CO)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O AIHHGFLJFSDSFZ-UHFFFAOYSA-N 0.000 description 1
- DADTZPCBJDBNMI-UHFFFAOYSA-N CN(C1)CC(C2)C1CN2c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound CN(C1)CC(C2)C1CN2c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O DADTZPCBJDBNMI-UHFFFAOYSA-N 0.000 description 1
- SFCOBAGMRQIHLU-UHFFFAOYSA-N CN(C=C1c(c(Cl)ccc2)c2Cl)c(nc(Nc2ccc(CN3CCNCC3)cc2)nc2)c2C1=O Chemical compound CN(C=C1c(c(Cl)ccc2)c2Cl)c(nc(Nc2ccc(CN3CCNCC3)cc2)nc2)c2C1=O SFCOBAGMRQIHLU-UHFFFAOYSA-N 0.000 description 1
- RQRXHKWTOPVAEL-UHFFFAOYSA-N CN(CC1)CCC1c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound CN(CC1)CCC1c(cc1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O RQRXHKWTOPVAEL-UHFFFAOYSA-N 0.000 description 1
- SMTWXSMNZNWQFB-GOSISDBHSA-N CN(CC1)[C@@H](CO)CN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O Chemical compound CN(CC1)[C@@H](CO)CN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O SMTWXSMNZNWQFB-GOSISDBHSA-N 0.000 description 1
- QNZSEOORKWJIQM-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc2cc(C3N4C5CC4C3)c5cc2)nc2)c2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc2cc(C3N4C5CC4C3)c5cc2)nc2)c2C1=O QNZSEOORKWJIQM-UHFFFAOYSA-N 0.000 description 1
- IQIXGUQEHPZWSI-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CN)c3Br)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CN)c3Br)ncc2C1=O IQIXGUQEHPZWSI-UHFFFAOYSA-N 0.000 description 1
- WMNTUWBEVOCCIL-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(F)c3N3CCNCC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(F)c3N3CCNCC3)ncc2C1=O WMNTUWBEVOCCIL-UHFFFAOYSA-N 0.000 description 1
- TURCTQHFIOYSDV-SFHVURJKSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3[C@H](COC)CNCC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3[C@H](COC)CNCC3)ncc2C1=O TURCTQHFIOYSDV-SFHVURJKSA-N 0.000 description 1
- LTHCLGLQFVDPSF-QGZVFWFLSA-N CN(CN1c(c(F)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3C[C@H](COC)NCC3)ncc2C1=O Chemical compound CN(CN1c(c(F)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3C[C@H](COC)NCC3)ncc2C1=O LTHCLGLQFVDPSF-QGZVFWFLSA-N 0.000 description 1
- CFSSLKDRPPPHQH-UHFFFAOYSA-N CN1C2c3cc(Nc(nc4N(C)CN5c(c(Cl)ccc6)c6Cl)ncc4C5=O)ccc3C1CC2 Chemical compound CN1C2c3cc(Nc(nc4N(C)CN5c(c(Cl)ccc6)c6Cl)ncc4C5=O)ccc3C1CC2 CFSSLKDRPPPHQH-UHFFFAOYSA-N 0.000 description 1
- UOUFXDKKRMNMIL-UHFFFAOYSA-N CN1Cc2cc(Nc(nc3N(C)CN4c(c(Cl)ccc5)c5Cl)ncc3C4=O)ccc2C2(CC2)C1 Chemical compound CN1Cc2cc(Nc(nc3N(C)CN4c(c(Cl)ccc5)c5Cl)ncc3C4=O)ccc2C2(CC2)C1 UOUFXDKKRMNMIL-UHFFFAOYSA-N 0.000 description 1
- NCZIVZOBMFGYTR-UHFFFAOYSA-N CNCC(N(CC1)CCN1c(c(CO)c1)ccc1Nc(nc1)nc(NCN2c(c(Cl)ccc3)c3Cl)c1C2=O)=O Chemical compound CNCC(N(CC1)CCN1c(c(CO)c1)ccc1Nc(nc1)nc(NCN2c(c(Cl)ccc3)c3Cl)c1C2=O)=O NCZIVZOBMFGYTR-UHFFFAOYSA-N 0.000 description 1
- WCAORSPCIBZKCC-LSDHHAIUSA-N C[C@@H](C1)NC[C@@H](C)N1c(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@@H](C1)NC[C@@H](C)N1c(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O WCAORSPCIBZKCC-LSDHHAIUSA-N 0.000 description 1
- CPYGWIHTHJOPLM-HDICACEKSA-N C[C@H](C1)O[C@@H](C)CN1c(c(CN(C)C)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@H](C1)O[C@@H](C)CN1c(c(CN(C)C)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O CPYGWIHTHJOPLM-HDICACEKSA-N 0.000 description 1
- NFMXSRRNFZGGLX-ROUUACIJSA-N Cc(cc(cc1)Nc(nc2)nc(N(C)CN3c(cccc4)c4Cl)c2C3=O)c1N1[C@@H](C2)CN[C@@H]2C1 Chemical compound Cc(cc(cc1)Nc(nc2)nc(N(C)CN3c(cccc4)c4Cl)c2C3=O)c1N1[C@@H](C2)CN[C@@H]2C1 NFMXSRRNFZGGLX-ROUUACIJSA-N 0.000 description 1
- LBXDCVKHTLOTSF-UHFFFAOYSA-N Cc(cc1)c(CN)cc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound Cc(cc1)c(CN)cc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O LBXDCVKHTLOTSF-UHFFFAOYSA-N 0.000 description 1
- CWVLJYRMFHIHPG-UHFFFAOYSA-N Cc(cc1)ccc1Nc(nc1N(C)CN2c3c(C)cccc3Cl)ncc1C2=O Chemical compound Cc(cc1)ccc1Nc(nc1N(C)CN2c3c(C)cccc3Cl)ncc1C2=O CWVLJYRMFHIHPG-UHFFFAOYSA-N 0.000 description 1
- JHXQTAUZLGOBGA-UHFFFAOYSA-N Cc(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound Cc(cc1)ccc1Nc(nc1NCN2c(c(Cl)ccc3)c3Cl)ncc1C2=O JHXQTAUZLGOBGA-UHFFFAOYSA-N 0.000 description 1
- ZDZWFQQAICCRME-IAGOWNOFSA-N Cc1cc(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)ccc1N1[C@H](C2)CN[C@H]2C1 Chemical compound Cc1cc(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)ccc1N1[C@H](C2)CN[C@H]2C1 ZDZWFQQAICCRME-IAGOWNOFSA-N 0.000 description 1
- PYJYZAOZEPFBOZ-UHFFFAOYSA-N O=C(c1cnc(Nc(cc2)ccc2N(CC2)CCN2C2CC2)nc1NC1)N1c(c(Cl)ccc1)c1Cl Chemical compound O=C(c1cnc(Nc(cc2)ccc2N(CC2)CCN2C2CC2)nc1NC1)N1c(c(Cl)ccc1)c1Cl PYJYZAOZEPFBOZ-UHFFFAOYSA-N 0.000 description 1
- CQJAAARGEMCIMK-UHFFFAOYSA-N O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1N(C1)C2CC2)N1c(c(Cl)ccc1)c1Cl Chemical compound O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1N(C1)C2CC2)N1c(c(Cl)ccc1)c1Cl CQJAAARGEMCIMK-UHFFFAOYSA-N 0.000 description 1
- AGLUZQIPIJTMGR-UHFFFAOYSA-N O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1N(C1)c2n[nH]cc2)N1c(c(Cl)ccc1)c1Cl Chemical compound O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1N(C1)c2n[nH]cc2)N1c(c(Cl)ccc1)c1Cl AGLUZQIPIJTMGR-UHFFFAOYSA-N 0.000 description 1
- ASDLTKWAOZXWBY-UHFFFAOYSA-N O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1NC1)N1c(cccc1)c1Cl Chemical compound O=C(c1cnc(Nc(cc2)ccc2N2CCNCC2)nc1NC1)N1c(cccc1)c1Cl ASDLTKWAOZXWBY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322602.2 | 2013-12-19 | ||
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014369457A1 AU2014369457A1 (en) | 2016-06-09 |
| AU2014369457B2 true AU2014369457B2 (en) | 2018-08-09 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014369457A Active AU2014369457B2 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (enExample) |
| EP (1) | EP3083625B1 (enExample) |
| JP (1) | JP6437559B2 (enExample) |
| KR (1) | KR102405462B1 (enExample) |
| CN (1) | CN105829315B (enExample) |
| AU (1) | AU2014369457B2 (enExample) |
| BR (1) | BR112016014151B1 (enExample) |
| CA (1) | CA2933755C (enExample) |
| CY (1) | CY1120035T1 (enExample) |
| DK (1) | DK3083625T3 (enExample) |
| ES (1) | ES2650013T3 (enExample) |
| GB (1) | GB201322602D0 (enExample) |
| HR (1) | HRP20180080T1 (enExample) |
| HU (1) | HUE037908T2 (enExample) |
| IL (1) | IL245672B (enExample) |
| LT (1) | LT3083625T (enExample) |
| MX (1) | MX371108B (enExample) |
| NO (1) | NO3083625T3 (enExample) |
| NZ (1) | NZ720178A (enExample) |
| PL (1) | PL3083625T3 (enExample) |
| PT (1) | PT3083625T (enExample) |
| RS (1) | RS56731B1 (enExample) |
| RU (1) | RU2691105C1 (enExample) |
| SG (1) | SG11201603814TA (enExample) |
| SI (1) | SI3083625T1 (enExample) |
| SM (1) | SMT201800020T1 (enExample) |
| WO (1) | WO2015092431A1 (enExample) |
| ZA (1) | ZA201603337B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168992A1 (en) * | 2015-04-21 | 2016-10-27 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
| EP3368538B1 (en) | 2015-11-01 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| WO2018090939A1 (zh) * | 2016-11-16 | 2018-05-24 | 上海瑛派药业有限公司 | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| CN110198943B (zh) * | 2017-01-23 | 2021-04-16 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| US20200108074A1 (en) | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| US11345710B2 (en) | 2017-07-10 | 2022-05-31 | Impact Therapeutics (Shanghai), Inc | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN117534673A (zh) | 2017-11-01 | 2024-02-09 | 无锡智康弘义生物科技有限公司 | 作为Wee1抑制剂的大环类化合物及其应用 |
| EP3758706A4 (en) * | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF |
| CN112771049B (zh) * | 2018-09-27 | 2024-01-26 | 贝达药业股份有限公司 | Fgfr4抑制剂及其应用 |
| CN112955454A (zh) | 2018-10-26 | 2021-06-11 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用 |
| AU2019413360B2 (en) | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20220194960A1 (en) | 2019-03-22 | 2022-06-23 | Shouyao Holdings (beijing) Co., Ltd. | Wee1 inhibitor and preparation and use thereof |
| MX2021012418A (es) | 2019-04-09 | 2021-11-12 | Nuvation Bio Inc | Compuestos heterociclicos y sus usos. |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP3952879A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2020221358A1 (zh) | 2019-04-30 | 2020-11-05 | 石家庄智康弘仁新药开发有限公司 | Wee1抑制剂化合物的晶型及其应用 |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| US20230159540A1 (en) | 2020-06-17 | 2023-05-25 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR |
| EP4221710A4 (en) * | 2020-10-01 | 2024-09-18 | University of Washington | DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21 |
| PH12023551406A1 (en) * | 2020-12-18 | 2024-01-22 | Glaxosmithkline Ip Dev Ltd | Chemical compounds useful for inhibiting nav1 .8 voltage-gated sodium channels and treating nav1 .8 mediated diseases |
| EP4263540A1 (en) * | 2020-12-18 | 2023-10-25 | GlaxoSmithKline Intellectual Property Development Limited | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
| CN117222648A (zh) | 2021-04-30 | 2023-12-12 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物及其制备方法和用途 |
| US12161722B2 (en) | 2021-06-25 | 2024-12-10 | Korea Research Institute Of Chemical Technology | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| RU2006136082A (ru) | 2004-03-15 | 2008-04-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| JP5411847B2 (ja) | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| HRP20161536T1 (hr) | 2007-06-15 | 2016-12-30 | Msd K.K. | Derivat bicikloanilina |
| JPWO2009054332A1 (ja) * | 2007-10-23 | 2011-03-03 | 萬有製薬株式会社 | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| EP2376494A4 (en) * | 2008-12-12 | 2012-07-11 | Msd Kk | DIHYDROPYRIMIDOPYRIMIDINDERIVATE |
| EP2376493B1 (en) | 2008-12-12 | 2016-10-05 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| ES2559224T3 (es) * | 2010-12-06 | 2016-02-11 | Glaxo Group Limited | Compuestos de pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por Lp-PLA2 |
| AR084515A1 (es) | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| EP2731953A1 (en) | 2011-07-15 | 2014-05-21 | Abbvie Inc. | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| WO2013013031A1 (en) * | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| CA2851640A1 (en) | 2011-10-20 | 2013-04-25 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| JP2015511245A (ja) * | 2012-02-23 | 2015-04-16 | アッヴィ・インコーポレイテッド | ピリドピリミジノン系キナーゼ阻害薬 |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
-
2016
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014369457B2 (en) | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | |
| US10766903B2 (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| JP6412920B2 (ja) | ２−アミノピリド［４，３−Ｄ］ピリミジン−５−オン誘導体及びＷｅｅ−１阻害薬としてのそれらの使用 | |
| WO2018011569A1 (en) | Wee-1 inhibiting pyrazolopyrimidinone compounds | |
| WO2018011570A1 (en) | Wee-1 inhibiting pyridopyrimidinone compounds | |
| CA3199082A1 (en) | Heterocyclic spiro compounds and methods of use | |
| EP3746432B1 (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| WO2015019037A1 (en) | Pharmaceutical compounds | |
| HK1227877B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK1227877A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |